MetaCap

CAMP4 Therapeutics (CAMP) vs Turn Therapeutics (TTRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Turn Therapeutics (TTRX) has outperformed CAMP4 Therapeutics (CAMP) over the past year, gaining 147.6% versus a gain of 30.7%. Turn Therapeutics is the larger company by market cap ($247.5 million vs $237.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAMP+30.69%TTRX+147.55%
+388%+176%-35%
Nov 21, 20251 yearNov 20, 2026
CAMP+2.16%TTRX+8.66%
+109%+19%-71%
Oct 6, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAMP versus TTRX key metrics
MetricCAMPTTRX
Share price$3.79$8.10
Market cap$237.84M$247.49M
1-day change-5.25%-6.31%
YTD return-38.17%+105.46%
1-year return+30.69%+147.55%
EPS (TTM)$-2.11$-0.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.50M—
Revenue growth (YoY)+436.50%—
Net income (latest FY)$-80.40M$-3.19M
Operating margin-1502.43%—
Net margin-2298.54%—
52-week high$7.75$16.45
52-week low$2.90$2.70
Distance from 52-week high-51.10%-50.79%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+169.66%+208.83%
Average volume238.88K119.32K
Shares outstanding62.75M30.57M
Employees482
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TTRX has outperformed CAMP by 116.9 percentage points over the past year.

About CAMP4 Therapeutics

CAMP stock →

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees

About Turn Therapeutics

TTRX stock →

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

CAMP vs TTRX FAQ

Which is bigger, CAMP4 Therapeutics or Turn Therapeutics?

Turn Therapeutics (TTRX) is larger, with a market capitalization of $247.49M compared with $237.84M for CAMP4 Therapeutics (CAMP).

Which stock has performed better over the past year, CAMP or TTRX?

TTRX returned +147.55% over the past 12 months, compared with +30.69% for CAMP (price return, excluding dividends). Past performance does not predict future results.

Are CAMP4 Therapeutics and Turn Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons